UCAR T-cell Clinical Trials

3 actively recruiting trials

Pipeline

Early 1: 1Phase 1: 2

Top Sponsors

Tianjin Huanhu Hospital1
The Children's Hospital of Zhejiang University School of Medicine1
Institute of Hematology & Blood Diseases Hospital, China1

Indications

Systemic Sclerosis (SSc)2
Lupus2
Multiple Sclerosis2
ANCA Associated Systemic Vasculitis1
SLE-ITP1

Other3 trials

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Phase 1

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.